Neurogene (NGNE) AI Stock Analysis

• Market Cap: $306.21M
• Dividend Yield: N/A
• Average Volume (3M): 220.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.85
• Revenue Growth: N/A
• EPS Growth: -140.77%
• Country: US
• Employees: 107
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -1.08
• Shares Outstanding: 14,262,066
• 10 Day Avg. Volume: 143,353
• 30 Day Avg. Volume: 220,276
• PEG Ratio: 3.06
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.26
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 67.29
• Enterprise Value/Gross Profit: -16.80
• Enterprise Value/Ebitda: -0.89
• 1Y Price Target: $38.20
• Price Target Upside: 69.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 34 Underperform
• Price Target: ―

Neurogene's overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.

Positive Factors

FDA Alignment

Alignment with FDA in writing confirms that Neurogene will not need to utilize a matched placebo for its pivotal trial; patients will be able to serve as their own controls, clarifying the developmental path forward for Neurogene.

Safety Profile

The selected go-forward low dose of NGN-401 appears to be significantly safer vs. high-dose NGN-401.

Trial Design

Neurogene's trial design includes younger patients starting from 3 years, which could differentiate it from competitors.

Negative Factors

Adverse Events

High-dose NGN-401 led to the treatment-related serious adverse event (SAE); the other high-dose patients experienced Grade 2 and 3 treatment-emergent adverse events (TEAEs) of ALT and AST elevation.

Competitor Data

Despite challenges in direct comparisons due to the heterogeneity of Rett patients, TSHA's success suggests promising implications for Neurogene Inc.

Neurogene Business Overview & Revenue Model

Company Description

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

How the Company Makes Money

Neurogene makes money primarily through the development and commercialization of its gene therapy products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop and market its therapies, and potential sales of approved treatments. Neurogene may also receive funding through research grants, collaborations with academic institutions, and milestone payments from its strategic partnerships, which support its ongoing research and development efforts.

Neurogene Financial Statement Overview

Summary

Neurogene faces significant financial challenges typical of early-stage biotech firms, with no revenue and substantial net losses due to high R&D expenses. Despite a strong liquidity position, the company relies heavily on external financing, and historical negative equity highlights financial vulnerabilities.

Income Statement

Neurogene has consistently reported zero revenue over the years, highlighting the early-stage nature of its research-focused operations. The company faces substantial net losses, which have increased over time, indicating high operating expenses without corresponding income. This consistent lack of revenue and growing net losses reflect significant financial challenges.

Balance Sheet

The balance sheet shows a strong liquidity position with significant cash reserves compared to total debt, evidenced by healthy net debt figures. However, the company's equity ratio has been negative in recent years due to significant accumulated losses, although it turned positive in 2023 and 2024. The high cash position provides some stability, but the negative equity in the past highlights financial distress.

Cash Flow

Neurogene's cash flow statements indicate negative operating and free cash flows, consistent with its status as a pre-revenue biotech firm. The company relies heavily on financing activities for cash inflows, which is unsustainable long-term. While free cash flow has improved marginally, the negative cash flow from operations poses a significant risk.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	925.00K	0.00	0.00	0.00	0.00
Gross Profit	-2.32M	-3.26M	-3.20M	-2.28M	-1.82M
EBITDA	-71.89M	-52.29M	-51.99M	-49.59M	-31.46M
Net Income	-75.14M	-36.32M	-55.19M	-50.52M	-33.28M
Balance Sheet
Total Assets	335.73M	222.57M	109.27M	101.49M	210.52M
Cash, Cash Equivalents and Short-Term Investments	312.40M	197.16M	82.02M	70.54M	192.56M
Total Debt	12.43M	16.25M	4.69M	5.21M	12.12M
Total Liabilities	25.36M	36.55M	255.00M	193.36M	19.30M
Stockholders Equity	310.38M	186.02M	-145.74M	-91.88M	191.22M
Cash Flow
Free Cash Flow	-71.41M	-51.74M	-55.05M	-64.77M	-26.79M
Operating Cash Flow	-70.60M	-51.42M	-52.82M	-46.40M	-24.57M
Investing Cash Flow	-125.26M	25.64M	-2.23M	-18.37M	-2.22M
Financing Cash Flow	184.07M	92.48M	66.53M	51.06M	77.14M

Neurogene Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Positive. The current price of 22.6 is above the 20-day moving average (MA) of 19.37, above the 50-day MA of 18.72, and below the 200-day MA of 23.66, indicating a neutral trend. The MACD of 1.12 indicates Negative momentum. The RSI at 62.61 is Neutral, neither overbought nor oversold. The STOCH value of 79.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NGNE.

Neurogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRQR	57 Neutral	$248.30M	―	-52.64%	―	82.38%	3.63%
LYEL	52 Neutral	$134.75M	―	-71.20%	―	-4.41%	-38.08%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
FDMT	46 Neutral	$192.71M	―	-32.97%	―	―	―
IKT	46 Neutral	$138.28M	―	-79.02%	―	-100.00%	38.72%
KRRO	45 Neutral	$118.88M	―	-60.22%	―	―	85.19%
NGNE	34 Underperform	$306.21M	―	-34.97%	―	―	-140.77%

Neurogene Corporate Events

Neurogene Highlights Progress in Rett Syndrome Program

Neurogene has updated its corporate presentation, highlighting the progress and future plans for its NGN-401 program for Rett syndrome, which is currently in Phase 1/2 clinical trials. The company is leveraging its proprietary EXACT technology and in-house manufacturing to advance its pipeline and explore market opportunities, positioning itself strategically in the biopharmaceutical sector.